20-F: Zepp Health Corp. Files 20-F, Details Financial Performance and Risks for 2024

Sentiment:

Annual Results


Zepp Health Corporation's 20-F filing provides a comprehensive overview of the company's financial performance, operational structure, and associated risks for the fiscal year ended December 31, 2024.

Worse than expectedThe company's revenue decreased by 48.3% compared to the previous year.The company's net loss increased significantly compared to the previous year.

Summary

  • Zepp Health Corporation, a global smart wearable and health technology leader, filed its 20-F report for the fiscal year ended December 31, 2024.
  • The company operates through subsidiaries and VIEs, with a significant portion of its revenue generated in China.
  • Zepp Health changed its reporting currency from Renminbi to U.S. dollars starting in the second quarter of 2024 to better reflect its performance.
  • The company shipped 4.0 million units of smart wearable devices in 2024.
  • Revenues decreased by 48.3% to US$182.6 million, primarily due to a decline in Xiaomi Wearable Products sales.
  • The gross profit decreased by 24.0% to US$70.2 million, but the gross margin increased to 38.5%.
  • The company recorded a net loss of US$75.8 million for the year.
  • As of December 31, 2024, cash, cash equivalents, and restricted cash totaled US$110.7 million.
  • The company is subject to various risks, including competition, supply chain disruptions, and regulatory uncertainties in China.
  • Zepp Health is committed to environmental, social, and governance (ESG) initiatives.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positives such as improved gross margin and a focus on ESG, the significant revenue decline and net loss raise concerns. The company faces numerous risks and uncertainties, contributing to a cautious outlook.

Positives

  • Gross margin increased to 38.5% in 2024, indicating improved profitability on products sold.
  • Research and development expenses decreased by 10.4%, suggesting improved efficiency in R&D spending.
  • The company is actively pursuing international expansion and brand recognition initiatives.
  • The company has a strong focus on data privacy and security, with established internal policies and certifications.
  • The company is committed to ESG initiatives, including environmental sustainability, social responsibility, and corporate governance.

Negatives

  • Revenues decreased by 48.3% in 2024, indicating a significant decline in sales.
  • Net loss amounted to US$75.8 million, reflecting financial challenges.
  • Sales of Xiaomi Wearable Products declined significantly, impacting overall revenue.
  • The company faces intense competition in the smart wearables market.
  • The company relies on contract manufacturers, which could lead to supply chain disruptions.

Risks

  • Failure to successfully develop and commercialize new products and services.
  • Inability to promote brands and protect reputation.
  • Supply shortages and disruptions due to reliance on limited suppliers.
  • Intense competition in the smart wearables market.
  • Failure to anticipate and satisfy consumer preferences.
  • Reliance on contractual arrangements with VIEs, which may not be as effective as direct ownership.
  • Uncertainties regarding the interpretation and application of PRC laws and regulations.
  • Potential delisting of ADSs due to failure to comply with NYSE minimum price requirements.
  • Cybersecurity incidents and disruptions of information technology systems.
  • The PRC governments significant oversight and discretion over our business operation could result in a material adverse change in our operations and the value of our ADSs.

Future Outlook

The company plans to continue expanding its international presence, enhancing brand recognition, and investing in research and development to drive future growth.

Management Comments

  • The company is committed to investing in new technologies and AI to maintain its competitive edge against its peers.
  • The company is committed to investing efficiently in marketing and branding to ensure sustainable growth.
  • The company will continue to manage working capital tightly.

Industry Context

The smart wearables market is highly competitive, with numerous participants including specialized consumer electronics companies, large consumer electronics companies, and traditional health and fitness companies.

Comparison to Industry Standards

  • Competitors in the smart wearables market include Fitbit, Garmin, Apple, Samsung, and Huawei.
  • Zepp Health faces competition from local providers in various regions.
  • The company's success depends on factors such as brand recognition, product offerings, functionality, sales and distribution, data accuracy, sensor technology, user services, and pricing.
  • Zepp Health's large user base and proprietary algorithms provide a competitive advantage.

Related Party Transactions

  • The company has significant related party transactions with Xiaomi and its affiliates.
  • The company purchased raw materials from Whale Microelectronics Co., Ltd., a subsidiary of Jiangsu Yitong.
  • The company transferred technologies related to Huangshan-2/2S smart wearable chips to Whale Microelectronics Co., Ltd.

Stakeholder Impact

  • Shareholders may experience fluctuations in the value of their investments due to market volatility and company performance.
  • Employees may be affected by changes in company strategy and resource allocation.
  • Customers may benefit from new and innovative products and services.
  • Suppliers and contract manufacturers may be impacted by changes in the company's supply chain and production plans.

Next Steps

  • The company plans to continue expanding its international presence.
  • The company plans to enhance brand recognition.
  • The company plans to invest in research and development.

Key Dates

DateDescription
December 27, 2013Anhui Huami was incorporated in the PRC.
December 2013Zepp Health commenced operations in China.
December 2014Zepp Health Corporation was incorporated in the Cayman Islands.
February 8, 2018Zepp Health's ADSs commenced trading on the NYSE.
January 1, 2020The Foreign Investment Law took effect in China.
August 2020Zepp brand was introduced.
December 18, 2020The Holding Foreign Companies Accountable Act (HFCAA) was enacted.
February 2021Zepp Health rebranded from Huami Corporation.
February 15, 2022Measures for Cybersecurity Review became effective.
March 17, 2022Board approved special cash dividends of US$0.025 per ordinary share.
April 2022Cash dividends were paid to shareholders.
May 2022SEC listed Zepp Health as a Commission-Identified Issuer under the HFCAA.
December 15, 2022PCAOB issued a report removing mainland China and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms.
February 17, 2023CSRC released Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies.
March 31, 2023Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies took effect.
April 30, 2024Zepp Health received a letter from the NYSE regarding non-compliance with continued listing standards.
September 16, 2024Zepp Health effected an ADS ratio change.
October 2, 2024Zepp Health received a letter from the NYSE confirming compliance with continued listing standards.
December 31, 2024Five-year transition period for foreign-invested enterprises expired.
January 2025Strategic cooperation agreement with Xiaomi expired.
February 28, 2025Xiaomi beneficially owned 15.6% of Zepp Health's total outstanding shares.
April 2, 2025President Trump announced the United States would impose a 10% tariff on most countries, effective on April 5, 2025, and individualized higher tariff rates on countries with which the United States has proportionately large trade deficits in goods, including, among others, a 34% additional tariff on goods imported from China.
April 5, 2025Effective date of the United States imposing a 10% tariff on most countries, and individualized higher tariff rates on countries with which the United States has proportionately large trade deficits in goods, including, among others, a 34% additional tariff on goods imported from China.

Keywords

Zepp Health, smart wearables, financial results, risk factors, 20-F filing, Amazfit, VIE structure, financial performance, corporate governance, data security

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.